L S van der Schoot1, J M P A van den Reek1, J M M Groenewoud2, M E Otero1, M D Njoo3, P M Ossenkoppele3, J M Mommers4, M I A Koetsier5, M A M Berends6, W P Arnold7, B Peters8, M P M Andriessen9, C W Den Hengst10, A L A Kuijpers11, E M G J de Jong1,12. 1. Department of Dermatology, Radboud University Medical Center, Nijmegen, the Netherlands. 2. Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands. 3. Department of Dermatology, Ziekenhuisgroep Twente, Almelo/Hengelo, the Netherlands. 4. Department of Dermatology, St Anna Ziekenhuis, Geldrop, the Netherlands. 5. Department of Dermatology, Gelre Ziekenhuizen, Apeldoorn, the Netherlands. 6. Department of Dermatology, Slingeland Ziekenhuis, Doetinchem, the Netherlands. 7. Department of Dermatology, Ziekenhuis Gelderse Vallei, Ede, the Netherlands. 8. Department of Dermatology, Ziekenhuis Rijnstate, Arnhem, the Netherlands. 9. Department of Dermatology, Jeroen Bosch Ziekenhuis, Den Bosch, the Netherlands. 10. Department of Dermatology, St Antonius Ziekenhuis, Woerden, the Netherlands. 11. Department of Dermatology, Máxima Medisch Centrum, Eindhoven, the Netherlands. 12. Radboud University, Nijmegen, the Netherlands.
Abstract
BACKGROUND: Female sex has been reported as a predictor for treatment discontinuation with biological therapies for psoriasis, although reasons remain unclear. It can be hypothesized that lower satisfaction with biological treatment in women might add to the lower drug survival rates. OBJECTIVES: To identify possible differences in satisfaction with biological treatment between female and male patients using the Treatment Satisfaction Questionnaire for Medication (TSQM). METHODS: Data of psoriasis patients treated with biologics were obtained from the prospective, multicentre, daily-practice BioCAPTURE registry. Longitudinal TSQM data were analysed by linear mixed models. Relevant patient characteristics were incorporated as possible confounding factors. Post hoc analysis of adverse events was performed in order to investigate differences between sexes. RESULTS: We included 315 patients with 396 corresponding treatment episodes (137 adalimumab, 90 etanercept, 137 ustekinumab, 24 secukinumab and 8 infliximab). Almost forty per cent of the patients were female. Women had significantly lower baseline PASI scores (P = 0.01). Longitudinal analyses demonstrated lower TSQM scores for 'side-effects' (P = 0.05) and 'global satisfaction' (P = 0.01) in female patients compared with male patients over 1 year of treatment. Women reported more relevant adverse events in the context of biologic treatment compared to men (rate ratio 1.79; P < 0.001), with more fungal (rate ratio 2.20; P = 0.001) and herpes simplex infections (rate ratio 3.25; P = 0.005). CONCLUSIONS: This study provides a prospective, longitudinal analysis of treatment satisfaction with biologics in female and male patients with psoriasis. Women were slightly less satisfied with treatment regarding side-effects and global satisfaction. Differences in treatment satisfaction and side-effects might add to the fact that women discontinue biological treatments more often.
BACKGROUND: Female sex has been reported as a predictor for treatment discontinuation with biological therapies for psoriasis, although reasons remain unclear. It can be hypothesized that lower satisfaction with biological treatment in women might add to the lower drug survival rates. OBJECTIVES: To identify possible differences in satisfaction with biological treatment between female and male patients using the Treatment Satisfaction Questionnaire for Medication (TSQM). METHODS: Data of psoriasispatients treated with biologics were obtained from the prospective, multicentre, daily-practice BioCAPTURE registry. Longitudinal TSQM data were analysed by linear mixed models. Relevant patient characteristics were incorporated as possible confounding factors. Post hoc analysis of adverse events was performed in order to investigate differences between sexes. RESULTS: We included 315 patients with 396 corresponding treatment episodes (137 adalimumab, 90 etanercept, 137 ustekinumab, 24 secukinumab and 8 infliximab). Almost forty per cent of the patients were female. Women had significantly lower baseline PASI scores (P = 0.01). Longitudinal analyses demonstrated lower TSQM scores for 'side-effects' (P = 0.05) and 'global satisfaction' (P = 0.01) in female patients compared with male patients over 1 year of treatment. Women reported more relevant adverse events in the context of biologic treatment compared to men (rate ratio 1.79; P < 0.001), with more fungal (rate ratio 2.20; P = 0.001) and herpes simplex infections (rate ratio 3.25; P = 0.005). CONCLUSIONS: This study provides a prospective, longitudinal analysis of treatment satisfaction with biologics in female and male patients with psoriasis. Women were slightly less satisfied with treatment regarding side-effects and global satisfaction. Differences in treatment satisfaction and side-effects might add to the fact that women discontinue biological treatments more often.
Authors: Marloes E van Muijen; S Atalay; L J van Vugt; L M D Vandermaesen; J M P A van den Reek; E M G J de Jong Journal: Drugs Real World Outcomes Date: 2021-03-28
Authors: Carlos Pelayo Hernández-Fernández; Gregorio Carretero; Raquel Rivera; Carlos Ferrándiz; Esteban Daudén; Pablo de Cueva; Isabel Belinchón; Francisco Javier Gómez-García; Enrique Herrera-Acosta; Diana P Ruiz-Genao; Marta Ferrán; Mercé Alsina; Ofelia Baniandrés-Rodríguez; José Luis Sánchez-Carazo; Rafael Botella-Estrada; Antonio Sahuquillo-Torralba; Lourdes Rodríguez; Jaime Vilar-Alejo; Carmen García-Donoso; José M Carrascosa; Mar Llamas-Velasco; Enrique Herrera-Ceballos; Jose Luis López-Estebaranz; Conrad Pujol-Marco; Miguel Angel Descalzo; Ignacio Garcia-Doval Journal: Acta Derm Venereol Date: 2021-01-04 Impact factor: 3.875